Results 51 to 60 of about 225,386 (188)

Research progress on the pathogenesis of Graves’ ophthalmopathy: Based on immunity, noncoding RNA and exosomes

Frontiers in Immunology, 2022
Graves’ ophthalmopathy (GO), also known as thyroid-associated ophthalmopathy, is a common potentially vision-threatening organ-specific autoimmune disease and the most common extrathyroidal manifestation of Graves’ disease.
Jingyi Zheng, Jingyi Zheng, Honghong Duan, Sufang You, Sufang You, Bo Liang, Yuping Chen, Yuping Chen, Huibin Huang   +8 more
doaj   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition (Adv. Sci. 4/2026)

Advanced Science, Volume 13, Issue 4, 19 January 2026.
An Allosteric Strategy for Thyroid Eye Disease This illustration depicts an aptamer (purple) binding to the target protein (white) at an allosteric site. This strategic binding induces a conformational change that acts as a shield, preventing pathogenic autoantibodies (red) from initiating the disease cascade, while leaving the protein's normal ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source

A Case of Euthyroid Graves’ Ophthalmopathy in a Patient Sero-Negative for TSH Receptor Autoantibody

Case Reports in Endocrinology, 2018
We report of a case of Graves’ ophthalmopathy presented solely with symptoms of the eyes with normal thyroid function tests and negative immunoreactive TSH receptor autoantibody.
Asami Hotta, Tomohiro Tanaka, Haruka Kato, Shota Kakoi, Yuki Shimizu, Chie Hasegawa, Akiko Hayakawa, Satoshi Yasuda, Kento Ogawa, Shunsuke Ito, Hideomi Ohguchi, Takashi Yagi, Hiroyuki Koyama, Mihoko Kawamura, Kazuhiko Sugitani, Yuichiro Ogura, Takashi Joh, Kenro Imaeda   +17 more
doaj   +1 more source

Immunological Aspects of Graves’ Ophthalmopathy [PDF]

BioMed Research International, 2019
The body’s autoimmune process is involved in the development of Graves’ disease (GD), which is manifested by an overactive thyroid gland. In some patients, autoreactive inflammatory reactions contribute to the development of symptoms such as thyroid ophthalmopathy, and the subsequent signs and symptoms are derived from the expansion of orbital adipose ...
Łacheta, Dominika, Piotr Stefan Miśkiewicz, Alicja Głuszko, Grażyna Joanna Nowicka, Marta Katarzyna Struga, Kantor, Ireneusz, Poślednik, Krzysztof, Mirza, Shafaq, Mirosław Jerzy Szczepański   +8 more
openaire   +2 more sources

A Pruritic Predicament: An Unusual Presentation of Graves’ Disease Complicated by Pregnancy

Case Reports in Medicine, Volume 2026, Issue 1, 2026.
Pruritus is a known but uncommon symptom of hyperthyroidism that can be misinterpreted or overlooked in a patient presentation. This is a case report of a 40‐year‐old female who presents with a 3‐month history of severe, worsening pruritus. Further history demonstrated potential signs of hyperthyroidism, and laboratory values demonstrated low TSH ...
Rob Lawless, Evan Smith, Camryn Slone, Thaddeus Salmon, Semonti Nandi   +4 more
wiley   +1 more source

Hypothyroid Graves’ Ophthalmopathy: Report of Two Cases

Endocrinology Research and Practice, 2007
Graves’ disease is an autoimmune disorder of the thyroid gland. Ophthalmopathy is the most common peripheral manifestation of Graves’ disease. It is a very rare condition that a Graves’ patient presents with spontaneous hypothyroidism.
Barış Akıncı, Tevfik Demir, Abdurrahman Çömlekçi   +2 more
doaj   +2 more sources

Lugol’s Iodine as a Key Treatment in Transient Gestational Thyrotoxicosis: A Case Report

Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.
Introduction Transient gestational thyrotoxicosis (TGT) occurs when human chorionic gonadotropin (hCG) directly stimulates the maternal thyroid gland during the first trimester of pregnancy. We report a case of complicated TGT in a young woman who required treatment with Lugol’s solution.
Mariam Mabrouk, Najla Bchir, Dorra El Guiche, Anaam Ben Chehida, Emna Mraihi, Chadia Zouaoui, Haroun Ouertani, Mohammad Shahangir Biswas   +7 more
wiley   +1 more source

Pulse dexamethasone therapy versus pulse methylprednisolone therapy for treatment of Graves′s ophthalmopathy

Indian Journal of Endocrinology and Metabolism, 2013
Pulse methylprednisolone therapy is the recommended therapy for moderate to severe and active ophthalmopathy, but high dose pulse methylprednisolone therapy is marred by the chances of fulminant hepatic failure and the high cost of therapy. Dexamethasone
Rajeev Philip, Sanjay Saran, Manish Gutch, Pushpaltha Agroyia, Rajiv Tyagi, Keshavkumar Gupta   +5 more
doaj   +1 more source

Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development

Taiwan Journal of Ophthalmology, 2020
Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of toxic diffuse goiter (Graves' disease), also known as Graves' ophthalmopathy/orbitopathy. As an organ-specific autoimmune disease, the pathogenesis of TAO is still
Yazhuo Huang, Sijie Fang, Shuo Zhang, Huifang Zhou   +3 more
doaj   +1 more source

Unilateral Graves’ Disease Developing During Treatment With Tirzepatide in a Patient With Diabetes: A Case Report

Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.
Background Tirzepatide is a dual agonist of the glucose‐dependent insulinotropic polypeptide (GIP) receptor and glucagon‐like peptide‐1 (GLP‐1) receptor, demonstrates significant efficacy in lowering blood glucose levels and reducing body weight. Consequently, its use has increased among patients with type 2 diabetes and obesity.
Yusuke Deto, Ryo Hasegawa, Shoya Ino, Satoru Shibata, Kouhei Ohno, Takahito Itoh, Tomoaki Matsumoto, Takayuki Miki, Kalyani Sen   +8 more
wiley   +1 more source